AUTL Autolus Therapeutics plc

  1. Stocks
  2. Healthcare
  3. NASDAQ: AUTL

Price (delayed)

$4.19

Market cap

$1.11B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.2

Enterprise value

$1.1B

autolus is a private biopharmaceutical company, focused on the development and commercialisation of engineered t-cell immunotherapy products with extreme efficacy in the treatment of life-threatening cancers. we are building a ...

Highlights
The EPS has grown by 24% year-on-year but it has declined by 22% since the previous quarter
The company's gross profit has shrunk by 73% YoY and by 69% QoQ
Autolus Therapeutics's revenue has plunged by 73% YoY and by 69% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: https://www.autolus.com/
Peers: OCX OGEN OLMA OMER

Key stats

What are the main financial stats of AUTL
Market
Shares outstanding
265.93M
Market cap
$1.11B
Enterprise value
$1.1B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.54
Price to sales (P/S)
429.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
646.5
Earnings
Revenue
$1.7M
EBIT
-$163.34M
EBITDA
-$152.71M
Free cash flow
-$156.57M
Per share
EPS
-$1.2
Free cash flow per share
-$0.9
Book value per share
$0.64
Revenue per share
$0.01
TBVPS
$2.16
Balance sheet
Total assets
$375.38M
Total liabilities
$263.91M
Debt
$223.87M
Equity
$111.47M
Working capital
$230.57M
Liquidity
Debt to equity
2.01
Current ratio
6.15
Quick ratio
5.37
Net debt/EBITDA
0.11
Margins
EBITDA margin
-8,993.6%
Gross margin
100%
Net margin
-12,272.3%
Operating margin
-10,583.1%
Efficiency
Return on assets
-49.3%
Return on equity
-105.7%
Return on invested capital
-57.2%
Return on capital employed
-49.4%
Return on sales
-9,619.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

AUTL stock price

How has the Autolus Therapeutics stock price performed over time
Intraday
1.95%
1 week
4.75%
1 month
-23.68%
1 year
113.78%
YTD
-34.94%
QTD
-34.33%

Financial performance

How have Autolus Therapeutics's revenue and profit performed over time
Revenue
$1.7M
Gross profit
$1.7M
Operating income
-$179.7M
Net income
-$208.38M
Gross margin
100%
Net margin
-12,272.3%
The company's gross profit has shrunk by 73% YoY and by 69% QoQ
Autolus Therapeutics's revenue has plunged by 73% YoY and by 69% from the previous quarter
Autolus Therapeutics's net income has decreased by 40% YoY and by 32% QoQ
Autolus Therapeutics's operating income has decreased by 25% YoY and by 19% QoQ

Growth

What is Autolus Therapeutics's growth rate over time

Valuation

What is Autolus Therapeutics stock price valuation
P/E
N/A
P/B
6.54
P/S
429.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
646.5
The EPS has grown by 24% year-on-year but it has declined by 22% since the previous quarter
AUTL's price to book (P/B) is 197% higher than its 5-year quarterly average of 2.2 and 72% higher than its last 4 quarters average of 3.8
Autolus Therapeutics's equity has shrunk by 63% YoY and by 38% QoQ
AUTL's price to sales (P/S) is 107% higher than its last 4 quarters average of 207.8 and 84% higher than its 5-year quarterly average of 233.9
Autolus Therapeutics's revenue has plunged by 73% YoY and by 69% from the previous quarter

Efficiency

How efficient is Autolus Therapeutics business performance
The return on equity has dropped by 68% year-on-year and by 63% since the previous quarter
Autolus Therapeutics's ROIC has soared by 54% YoY but it has decreased by 12% from the previous quarter
Autolus Therapeutics's return on assets has decreased by 41% QoQ and by 19% YoY

Dividends

What is AUTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for AUTL.

Financial health

How did Autolus Therapeutics financials performed over time
The company's total assets is 42% higher than its total liabilities
AUTL's total liabilities is up by 38% year-on-year and by 17% since the previous quarter
Autolus Therapeutics's quick ratio has decreased by 35% YoY and by 21% QoQ
AUTL's debt is 101% greater than its equity
The company's debt to equity has surged by 88% QoQ
Autolus Therapeutics's equity has shrunk by 63% YoY and by 38% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.